Cronos Group
CRON
3.24
-0.05
-1.37%
Cronos Group
US · CRON
#3133 by market cap
Listed 1970
3.24
-0.05
-1.37%
Live - 5344 symbols - heartbeat 269s ago
· 2026-10-08 05:42
Pre-market
3.19
-1.51%
After-hours
3.25
+0.31%
- Market cap
- 1.19B
- P/E (TTM)i
- 17.05
- P/Bi
- 1.12
- EPSi
- -0.02
- Div yieldi
- 0.00%
- 52W posi
- 72%
Reader sentiment
Are you bullish or bearish on CRON?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 14.71, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +24.63% YoY
Margins
- Gross margin
- 42.81%
- Operating margin
- -13.30%
- Net margin
- -6.44%
Key ratios & quality
- Altman Z-Scorei
- 14.71
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.12M | 23.75M | 46.72M | 64.56M | 86.75M | 87.24M | 117.62M | 146.59M |
| Gross profit | 6.21M | -17.60M | -25.83M | -17.59M | 15.44M | 11.91M | 25.20M | 62.76M |
| Selling & admin expenses | 24.04M | 116.15M | 130.32M | 121.68M | 100.73M | 80.93M | 76.82M | 70.81M |
| Research & development | 1.81M | 12.16M | 20.37M | 21.84M | 13.13M | 5.84M | 4.23M | 4.45M |
| Operating profit | -20.45M | -147.99M | -179.39M | -165.53M | -104.39M | -79.91M | -59.55M | -19.50M |
| Pretax profit | -20.92M | 1.17B | -73.27M | -128.51M | -121.00M | -73.67M | 36.59M | -17.12M |
| Tax | 0 | 0 | 1.35M | -431.00K | 34.18M | -3.23M | -3.44M | -14.19M |
| Net profit | -21.82M | 1.17B | -75.27M | -397.20M | -168.73M | -74.55M | 40.02M | -2.93M |
| Basic EPS | 0 | 4 | 0 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.12 | 3.33 | -0.21 | -1.07 | -0.45 | -0.19 | 0.11 | -0.02 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 32.26M | 33.46M | 36.34M | 44.53M | 45.21M | 53.01M |
| Gross profit | 13.73M | 14.50M | 18.33M | 16.19M | 19.15M | 28.45M |
| Selling & admin expenses | 15.96M | 17.26M | 16.89M | 20.70M | 18.66M | 19.15M |
| Research & development | 793.00K | 929.00K | 1.35M | 1.38M | 1.41M | 1.22M |
| Operating profit | -3.52M | -4.56M | -5.03M | -6.40M | -1.46M | 7.60M |
| Pretax profit | 7.27M | -39.01M | 27.01M | -12.39M | 18.14M | 35.71M |
| Tax | -455.00K | -525.00K | -1.32M | -11.90M | 2.43M | 51.00K |
| Net profit | 7.72M | -38.48M | 28.32M | -491.00K | 15.71M | 35.66M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.02 | -0.10 | 0.07 | 0.00 | 0.04 | 0.09 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 39.94M | 1.57B | 1.37B | 1.08B | 960.16M | 933.31M | 936.11M | 944.09M |
| Cash & ST investments | 23.93M | 1.51B | 1.29B | 1.00B | 877.72M | 861.53M | 858.81M | 831.79M |
| Inventory | 7.39M | 38.04M | 44.00M | 32.80M | 37.56M | 30.50M | 33.15M | 46.75M |
| Total assets | 183.47M | 2.09B | 1.93B | 1.40B | 1.21B | 1.14B | 1.17B | 1.20B |
| Total current liabilities | 33.27M | 332.89M | 206.83M | 54.37M | 68.12M | 41.40M | 49.70M | 48.19M |
| Short-term debt | 30.00K | 427.00K | 1.32M | 2.71M | 1.33M | 994.00K | 1.03M | 337.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 34,922,000.00 | 341,412,000.00 | 217,514,000.00 | 63,462,000.00 | 72,045,000.00 | 44,142,000.00 | 55,330,000.00 | 54,181,000.00 |
| Total equity | 148.55M | 1.75B | 1.71B | 1.33B | 1.14B | 1.10B | 1.11B | 1.14B |
| Retained earnings | -27.95M | 1.14B | 1.06B | 659.42M | 490.68M | 416.72M | 457.71M | 447.76M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 918.58M | 927.15M | 922.15M | 944.09M | 927.88M | 912.03M |
| Cash & ST investments | 837.82M | 834.42M | 824.17M | 831.79M | 821.86M | 797.02M |
| Inventory | 34.60M | 42.14M | 48.17M | 46.75M | 48.68M | 52.70M |
| Total assets | 1.15B | 1.18B | 1.18B | 1.20B | 1.17B | 1.18B |
| Total current liabilities | 33.05M | 37.61M | 41.07M | 48.19M | 42.42M | 56.36M |
| Short-term debt | 977.00K | 822.00K | 576.00K | 337.00K | 169.00K | 162.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 39,062,000.00 | 45,021,000.00 | 46,361,000.00 | 54,181,000.00 | 48,295,000.00 | 62,415,000.00 |
| Total equity | 1.11B | 1.13B | 1.13B | 1.14B | 1.12B | 1.12B |
| Retained earnings | 463.82M | 424.08M | 450.03M | 447.76M | 460.54M | 492.32M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.52M | -131.19M | -144.87M | -153.62M | -88.95M | -42.84M | 18.84M | 25.87M |
| Depreciation & amortization | 1.94M | 4.27M | 7.05M | 15.40M | 13.12M | 8.11M | 9.34M | 14.23M |
| Free cash flow | -96.10M | -170.15M | -180.26M | -165.88M | -93.98M | -46.26M | 5.69M | -190.00K |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 115.51M | -- | -- | -- | -- | 0 | 0 | -9.74M |
| Ending cash balance | 23.93M | 1.20B | 1.08B | 886.97M | 764.64M | 669.29M | 858.81M | 791.79M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -2.10M | 2.82M | 13.31M | 11.84M | 10.90M | 24.01M |
| Depreciation & amortization | 2.84M | 4.20M | 3.53M | 3.66M | 3.73M | 3.37M |
| Free cash flow | -17.45M | -1.02M | 8.72M | 9.56M | 8.93M | 22.23M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -3.61M | -1.86M | -4.27M | -16.73M | -16.13M |
| Ending cash balance | 797.82M | 794.42M | 784.17M | 791.79M | 821.86M | 467.02M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -12.44 | 122.46 | -4.23 | -25.99 | -13.60 | -6.59 | 3.80 | -0.88 |
| ROA %i | -10.24 | 102.23 | -3.64 | -23.84 | -12.93 | -6.29 | 3.56 | -0.80 |
| ROIC %i | -10.94 | 117.72 | -4.98 | -26.41 | -14.86 | -10.93 | -0.29 | -4.02 |
| 5-year avg ROE %i | -15.34 | 19.58 | 18.06 | 13.92 | 11.83 | 14.50 | -9.32 | -8.65 |
| EBIT margin %i | -115.32 | 4,914.45 | -156.44 | -533.50 | -146.40 | -91.60 | -50.63 | -13.30 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 4.84 | -- |
| Current ratioi | 1.20 | 4.73 | 6.63 | 19.86 | 14.10 | 22.54 | 18.84 | 19.59 |
| Quick ratioi | 0.89 | 4.57 | 6.36 | 19.09 | 13.44 | 21.68 | 17.88 | 18.45 |
| Debt / assetsi | 0.06 | 0.34 | 0.51 | 0.70 | 0.32 | 0.22 | 0.17 | 0.13 |
| LT debt / equityi | 0.06 | 0.38 | 0.50 | 0.53 | 0.22 | 0.14 | 0.09 | 0.11 |
| Interest coveragei | -- | 938.25 | -392.94 | -14,707.70 | -10,349.69 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | 286.24 | 145.77 | 74.64 | 54.00 | 23.14 | 22.13 | 19.11 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 4.61 | 1.73 | 3.34 | -0.88 | -0.17 | 6.51 |
| ROA %i | 4.37 | 1.63 | 3.06 | -0.80 | -0.16 | 5.94 |
| ROIC %i | 0.85 | -1.68 | 0.02 | -4.02 | -2.36 | 4.33 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -39.47 | -29.72 | -18.48 | -13.30 | -10.93 | -2.95 |
| FCF / sales %i | -- | -- | -- | -- | 16.42 | 27.61 |
| Current ratioi | 27.80 | 24.65 | 22.45 | 19.59 | 21.87 | 16.18 |
| Quick ratioi | 26.31 | 23.23 | 21.00 | 18.45 | 20.61 | 15.15 |
| Debt / assetsi | 0.16 | 0.17 | 0.15 | 0.13 | 0.11 | 0.11 |
| LT debt / equityi | 0.08 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Cannabis flower is the largest reported line at 73.98% of revenue, across 3 reported segments.
- The next-largest line, Cannabis extracts, is a distant second at 25.99% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Cannabis flower73.98%
Cannabis extracts25.99%
Quote time 2026-10-08 05:42:01 · For reference only, not investment advice and not tailored to your situation.